Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old.~* Idiopathic Membranous nephropathy proved by renal biopsy~* Persistent urinary protein excretion rate ≥3,5g/24 h and albuminemia \< 30g/l for at least 6 months with full dose of NIST~* Patient receiving a non immunosuppressive conventional treatment (antiproteinuric and antihypertensive blocking the rennin-angiotensine system, lipid-lowering statin) since at least 6 months.~* Patient has given its written consent~* Patient with social coverage (excepting AME)~* Use of an efficient contraception method for women in childbearing age.~Exclusion Criteria:~* Secondary membranous nephropathy~* Patient already in a clinical trial~* Patient received an immunosuppressive treatment within 3 months before the study~* Patient with chronic renal disease defined by estimated GFR by MDRD formula under 30ml/mn/1,73m²~* Pregnancy and breastfeeding~* HIV infection, HCV and HBV active infection~* Severe or evolving infections.~* Allergy or hypersensitivity to Rituximab or any component

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active comparator (Type: ACTIVE_COMPARATOR): Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
- experimental (Type: EXPERIMENTAL): NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)

Based on this trial design, predict the completion outcome and termination type (if applicable).